Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FluMist May Require Additional Phase III Trial To Expand Patient Population

This article was originally published in The Pink Sheet Daily

Executive Summary

MedImmune seeks to expand the indication for its intranasal flu vaccine to people ages 50 to 64; the company is waiting to see if FDA will accept new analyses of existing data in the target age group. MedImmune and Chiron suggest incentives to increase flu vaccine demand during a House committee hearing.

Related Content

Topics

UsernamePublicRestriction

Register

PS058170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel